Skip to main content
LUYAN PHARMA CO.,LTD logo

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 ISIN · CNE1000025W1 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-03-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
对外投资管理制度（2016年3月）
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and is a detailed internal policy document of the company regarding management and control of external investments. It includes sections on approval authority, decision management, execution and control, and information disclosure related to external investments. There are no financial statements, earnings data, or audit opinions present. The document is a governance or internal control policy rather than a financial report or announcement. It is not a report publication announcement or a certification. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to external investments.
2016-03-10 Chinese
第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 13th meeting of the 3rd Board of Directors of 鹭燕（福建）药业股份有限公司. It details the meeting date, attendance, and voting results on various internal governance policies such as stock trading management for directors and senior management, internal audit system, insider information registration, and external investment management. The document is a formal disclosure of board decisions and changes in internal governance rules, but it does not contain financial statements, audit opinions, or detailed management discussion. It is not a full annual or interim report, nor an earnings release or capital update. The content fits the category of Board/Management Information (MANG) as it relates to board meeting resolutions and governance decisions. The document length is short and focused on board meeting resolutions, confirming it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2016-03-10 Chinese
关于签署募集资金监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a fundraising supervision agreement related to the company's initial public offering (IPO) and the management of the raised funds. It details the amount raised, the bank accounts opened for the funds, the supervisory roles, and the agreements signed with banks and the sponsor. The document does not contain financial statements or detailed financial performance data but focuses on the regulatory and procedural aspects of fundraising and fund management. The document length is 3268 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it provides updates on fundraising activities and capital management.
2016-03-02 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 鹭燕（福建）药业股份有限公司 regarding abnormal stock trading fluctuations. It explains the situation, company verification, risk factors, and warnings to investors. The content focuses on stock trading behavior, risk disclosures, and company operational risks rather than financial statements or detailed financial results. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement related to stock trading and risk disclosure, typical of a Regulatory Filing (RNS). The document length is 7633 characters, which is substantial but the content is clearly an announcement rather than a full report. There is no indication of it being an Annual Report, Interim Report, or any other specific report type. Therefore, the best classification is Regulatory Filings (RNS).
2016-03-01 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding abnormal stock price fluctuations and provides detailed explanations and risk factors related to the company's business and market environment. It includes no financial statements or comprehensive financial data but focuses on stock trading behavior and risk disclosures. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about stock price movements and related risk factors. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-02-29 Chinese
国信证券股份有限公司关于公司使用募集资金置换预先投入募投项目自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion issued by Guosen Securities, the sponsor institution for a company's initial public offering, regarding the use of raised funds to replace self-raised funds previously invested in projects. It references regulatory compliance with Shenzhen Stock Exchange listing rules and includes detailed financial figures about the fundraising and project investments. The document is a specialized verification report related to the use of raised funds, not a full annual or interim financial report, nor an earnings release or management discussion. It is a standalone audit-related verification opinion on a specific financial matter, consistent with an Audit Report / Information filing. The document length is about 2500 characters, which is short but contains substantive audit verification content, not merely an announcement or certification letter. Therefore, it fits best under the Audit Report / Information (AR) category.
2016-02-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.